Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.

Abstract

Tumor mutational burden (TMB) is a biomarker that measures the number of somatic mutations in a tumor's genome. TMB has emerged as a predictor of response to immune checkpoint inhibitors (ICIs) in various cancer types, and several studies have shown that patients with high TMB have better outcomes when treated with programmed death-ligand 1-based therapies. Recently, the Food and Drug Administration has approved TMB as a companion diagnostic for the use of pembrolizumab in solid tumors. However, despite its potential, the use of TMB as a biomarker for immunotherapy efficacy is limited by several factors. Here we review the limitations of TMB in predicting immunotherapy outcomes in patients with cancer and discuss potential strategies to optimize its use in the clinic.

• Authors: X Wang, G Lamberti, A Di Federico, J Alessi, R Ferrara, M L Sholl, M M Awad, N Vokes, B Ricciuti
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) (Mar 26 2024) ISSN: 1569-8041 [Electronic] England
• PMID: 38537779 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2024 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.